Category: Dialysis
NxStage Medical founder & CEO Jeff Burbank tells MassDevice.com about its 4th-quarter and 2012 results, which topped Wall Street forecasts today, sending share prices up nearly 8% at their peak.
NxStage Medical (NSDQ:NXTM) shares jumped nearly 8% today after the medical device company reported Wall-Street-beating results for the 4th quarter and 2012.
NxStage Medical tops Wall Street's forecasts for both sales and losses, sending share prices up nearly 8% today.
NxStage Medical (NSDQ:NXTM) shares jumped nearly 8% today after the medical device company reported Wall-Street-beating results for the 4th quarter and 2012.
NxStage Medical touts its 3rd European regulatory win this month with CE Mark approval for its OneSite single needle dialysis technology.
Massachusetts medical device maker NxStage Medical (NSDQ:NXTM) is on a roll, notching its 3rd regulatory win this month with CE Mark approval in the European Union for its OneSite single needle for dialysis patients.
European Union regulators grant CE Mark approval to NxStage Medical's high-flow System 1 home hemodialysis technology, hard on the heels of its approval for nocturnal home dialysis across the pond.
NxStage Medical (NSDQ:NXTM) won CE Mark approval in Europe for its System 1 technology, which includes new high-flow capabilities to the portable hemodialysis system.
NxStage Medical CEO Jeff Burbank tells MassDevice.com about the medical device company's 'great step forward' as it plans to market its System 1 home hemodialysis device for nocturnal therapy in the European Union.
UPDATED Feb. 19, 2:00 p.m. with comments from NxStage CEO Jeff Burbank.
NxStage Medical notches CE Mark approval in the European Union for nocturnal use of its System 1 home hemodialysis device.
NxStage Medical (NSDQ:NXTM) said it won CE Mark approval in the European Union for its System 1 home hemodialysis device, saying it expects to begin marketing the device for that indication in the 2nd half of this year.
Shares of Stryker Corp. hit a 52-week high the day it issues a 26.5¢ dividend to shareholders.
Shares of Stryker (NYSE:SYK) hit a 52-week high yesterday, peaking at $64.46 apeice before closing at $63.88, down 0.2% on the day.
STK shares are up about 3% since the medical device company reported 4th-quarter and 2012 results Jan. 24. Stryker said yesteday that it plans to issue a 26.5¢ dividend to shareholders.
News Well,
MassDevice.com Earnings Roundup,
2012,
Dialysis,
Direct-to-Consumer,
Funding Roundup,
Neuromodulation/Neurostimulation,
Q4,
Regenerative Medicine,
Stem Cells,
Wall Street Beat,
Weight loss
